PEQUEUX Christel
Professeur associé
Agrégée
Faculté de Médecine
Département des sciences biomédicales et précliniques
GIGA Cancer - Tumours and development biology
- ULiège address
-
Bât. B23 Labo de biologie des tumeurs et du développement
Quartier Hôpital
avenue Hippocrate 13
4000 Liège 1
Belgique
- ULiège phone number
- +32 4 3662217
- ULiège Fax
- +32 4 3662936
-
Captcha : Put the image in the right direction
- Conseil sectoriel à la recherche et à la valorisation
- Sciences de la Santé
- Personal website (s)
- Research team website
- Personal website (s)
- PubMed link
- University degrees
-
2013: IFRES certification (Université de Liège)
2003: FELASA cat. C (Université de Liège)
2002: PhD in Sciences (Université de Liège)
1998: Certification in Molecular Endocrinology (University of Montpellier I )
1996: High School Agregation (Université de Liège)
1995: Master in Chemistry (Université de Liège)
Biography
Christel Pequeux dedicates her research in endocrinology and cancer. She completed her PhD in 2002 at the University of Liège (Belgium) under the supervision of Prof. Legros, in collaboration with Prof. North at the Dartmouth Medical School (NH, USA), investigating the role of neurohypophyseal hormones (oxytocin, vasopressin) in small cell lung cancer. Then, she moved to the laboratory of Prof. Foidart, Noël and Cataldo (ULiege) to study several cellular and molecular interactions occurring in tumor microenvironment, contributing to angiogenesis and lymphangiogenesis. She also studied the contribution of angiogenic factors to preeclampsia.
After a postdoctoral experience with Prof. Arnal and Lenfant (INSERM Toulouse, France) focused on estrogen receptor biology, she has been running her own team in the Laboratory of Biology, Tumors and Development (LBTD/GIGA-cancer) of the GIGA research institute of the University of Liège since 2013. She is currently Associate Professor at the Medicine Faculty of the University of Liège and Vice-President of the Department of Biomedical and Preclinical Sciences.
These last years, her research topics have brought fundamental and translational data to contribute to the development of menopause hormone treatment (MHT) with optimized benefit/risk ratio. In that view, she supervises research projects aiming at characterizing the impact of estrogens on several target tissues including breast cancer, mammary gland and endometrium, revealing their molecular mechanisms of action.
Finally, in addition to these studies in cancer field, she is also implicated in neuroscience aspects related to estrogens such as audition and neuroprotection. Based on their experimental evidence on neonatal hypoxic-ischemic encephalopathy, a fetal estrogen was granted by European Medicines Agency the orphan drug designation (ORPHA:137577).
Research field
- Sciences biomédicales
